Please note that if approved by a research manager this concept note will be published on the [MSF-OCA Research Management and Impact Tool (ReMIT)](http://remit.oca.msf.org). If you have any questions about ReMIT please email [remit@oca.msf.org](mailto:remit@oca.msf.org).

|  |  |  |
| --- | --- | --- |
| Proposed study title |  | |
| Research question  (Describe the main study question in 1 sentence) |  | |
| **Key objective**  (What you hope to achieve by doing the study) |  | |
| **Secondary objectives**  (if applicable) |  | |
| **Study topic**  (Check all that apply) | |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | |  | AMR |  | Maternal & women's health |  | Pneumonia | |  | Cholera |  | Measles |  | Sexual violence | |  | Ebola |  | Meningitis |  | Surgery | |  | Environmental contamination |  | Mental Health |  | Tuberculosis | |  | HIV |  | Mortality |  | Vaccination | |  | Leishmaniasis |  | NTDs (excluding Leishmaniasis) |  | VHF (excluding Ebola) | |  | Malaria |  | Neonatal & child health |  | WatSan | |  | Nutrition |  | Non-communicable diseases |  | Other |   **If other please state:** | |
| **Study location**  (Where you propose doing the study) |  | |
| **Conflict zone**  (Please state if any of your study sites are located in a conflict zone) | |  |  |  |  | | --- | --- | --- | --- | |  | Yes |  | No | | |
| **Context**  (Relevant to proposed locations – potential benefits & risks of using these sites)  1 paragraph |  | |
| **Background**  (Briefly outline “the problem” – why is it important to answer the study question? Has anyone else tried?)  1-2 paragraphs |  | |
| **Type of study**  (Check the methodology applies to your study)  See relevant reporting guidelines at the end of this concept note for guidance on study write-up | |  |  |  |  | | --- | --- | --- | --- | |  | Observational study |  | Mixed methods study | |  | Randomised trial |  | Qualitative research | |  | Systematic review |  | Quality improvement study | |  | Case report |  | Prediction model | |  | Diagnostic study |  | Other |   **If other, please state:** | |
| **Methods**  (Briefly outline how you propose to answer the study question. Specifically include who the study subjects will be and, if appropriate, how you plan to obtain consent and protect confidentiality) |  | |
| **Benefits**  (Likely benefits to participants, and to other projects / people) |  | |
| **Risks**  (Potential risks/harms to patients. Also consider risks to completing the study– e.g. operational constraints, cooperation of authorities) |  | |
| **Resources / Costs**  (List resources needed e.g. statistician, input from other specialists, field time. Budget not needed but include cost estimate if known) |  | |
| **Proposed duration**  (Give time estimates for each stage of study i.e. protocol development/ethical review/site preparation/training/data collection/analysis/write up etc. List proposed start/end date of each stage and any time restrictions) | **Study preparation:**  **Data collection:**  **Data analysis:**  **Write up:** | |
| **Principal Investigator**  (Contact details of those proposing the study) |  | |
| **MSF research team**  (Who else have you, or might you, involve?) |  | |
| **External partners**  (Give the name, position and institution of any external collaborators) |  | |
| **Competing interests**  **(**Declare any competing interests of the research team (inc collaborators) including if this work will contribute to an academic qualification) |  | |
| **Data management and sharing**  (Contact details of those responsible: see MSF’s Data Sharing policy including a template [annex] to be completed at protocol stage <http://www.msf.org/msf-data-sharing-policy> ) |  | |
| **Dissemination and implementation of research findings** | | |
| **1) Responsibility**  (Contact details of those responsible for disseminating and implementing findings) | |  |
| **2) Dissemination**  (How will the findings be disseminated?)  For guidance on dissemination please contact [barbara.nasto@london.msf.org](mailto:barbara.nasto@london.msf.org) | |  |
| **3) Implementation**  (How will any relevant findings be implemented in MSF and/or externally? | |  |

\*\* Please see a list of reporting guidelines below for studies commonly undertaken by MSF. These guidelines aim to improve the quality of research reporting and we thus expect to see them applied to the write up of MSF studies \*\*

* Observational studies (e.g. retrospective observational studies, cohort, case-control, cross sectional) – [STROBE](http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0040296) ([& extensions](http://www.equator-network.org/?post_type=eq_guidelines&eq_guidelines_study_design=0&eq_guidelines_clinical_specialty=0&eq_guidelines_report_section=0&s=+STROBE+extension&btn_submit=Search+Reporting+Guidelines))
* Randomised trials – [CONSORT](http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000251) ([& extensions](http://www.equator-network.org/reporting-guidelines/consort/))
* Systematic reviews – [PRISMA](http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000097) ([& extensions](http://www.equator-network.org/reporting-guidelines/prisma/))
* Case reports – [CARE](http://jmedicalcasereports.biomedcentral.com/articles/10.1186/1752-1947-7-223)
* Qualitative research – [SRQR](http://journals.lww.com/academicmedicine/Fulltext/2014/09000/Standards_for_Reporting_Qualitative_Research___A.21.aspx) ([& extensions](http://intqhc.oxfordjournals.org/content/19/6/349.long))
* Diagnostic studies – [STARD](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623764/)
* Quality improvement studies – [SQUIRE](http://qualitysafety.bmj.com/content/17/Suppl_1/i3.long)
* Prediction model studies - [TRIPOD](http://www.bmj.com/content/350/bmj.g7594.long)